Summary

The global Biologics CMO (Contract Manufacturing Organization) Services market is projected to grow from US$ 21789 million in 2025 to US$ 38731 million by 2032, at a CAGR of 8.7% (2026-2032), driven by critical product segments and diverse end‑use applications.
Biologics CMO (Contract Manufacturing Organization) Services refer to manufacturing services provided by contract manufacturing organizations under client agreements to biopharmaceutical companies, pharmaceutical companies, and other drug development organizations. These services primarily include biologic drug substance manufacturing, drug product manufacturing, aseptic fill-finish, and other GMP manufacturing activities. The service scope covers antibodies, vaccines, cell and gene therapies, and other biologics, and may support both clinical-stage and commercial-stage production. The market includes contract manufacturing services provided by independent third-party CMOs as well as external manufacturing services offered by in-house CMO business units of pharmaceutical and biopharmaceutical companies. Compared with CDMO services, CMO services are primarily focused on manufacturing execution and production capabilities and generally do not emphasize early-stage drug development, comprehensive process development, formulation development, or other R&D-intensive activities.
Biologics CMO (Contract Manufacturing Organization) services refer to GMP manufacturing services provided under contract to pharmaceutical companies, biotechnology companies, and other drug development organizations. These services primarily cover biologic drug substance (DS) manufacturing, drug product (DP) manufacturing, aseptic fill-finish, packaging, and related quality control activities. By provider type, the industry includes both independent CMOs whose core business is third-party contract manufacturing and in-house CMO business units of large pharmaceutical and biopharmaceutical companies that provide manufacturing capacity to external customers. Compared with CDMOs, CMOs place greater emphasis on process execution following technology transfer, scale-up manufacturing, quality control, and reliable supply, while early-stage drug discovery, systematic process development, and formulation development are generally not their primary functions.
By product type, biologics CMO services mainly cover antibodies, vaccines, cell and gene therapies, and other biologics. Antibodies represent one of the more mature contract manufacturing segments and typically involve mammalian cell culture, harvest, chromatography purification, viral clearance, and drug substance preparation. Vaccine manufacturing involves a wider range of production platforms and process technologies. Cell and gene therapies generally feature smaller batch sizes, more complex processes, stringent quality requirements, and highly customized manufacturing workflows. Consequently, facility design, equipment configuration, biosafety requirements, and quality systems vary significantly across different biologic modalities.
By manufacturing stage, the industry can be divided into biologic drug substance manufacturing and biologic drug product manufacturing. Drug substance manufacturing is generally the more technology- and capital-intensive segment and includes cell culture or microbial fermentation, separation, purification, and bulk drug substance storage. Drug product manufacturing primarily covers formulation, aseptic filling, lyophilization, and filling into vials, prefilled syringes, or cartridges. Some large CMOs have established integrated DS-to-DP manufacturing networks, while other specialized providers focus on large-scale drug substance manufacturing or specific activities such as sterile fill-finish.
Direct customers primarily include large pharmaceutical and biopharmaceutical companies, small and mid-sized pharmaceutical and biotechnology companies, and other drug development organizations. Large pharmaceutical companies generally maintain internal manufacturing capabilities but may outsource production due to capacity constraints, new product introductions, regional supply requirements, specialized manufacturing needs, or efforts to reduce fixed-asset investment. Small and mid-sized biotechnology companies tend to rely more heavily on external manufacturing resources, with CMOs supporting clinical supply, scale-up, and commercial production.
Biologics CMO is an industry characterized by high capital, technical, and regulatory barriers. Mammalian cell culture is a core platform for antibodies and many recombinant proteins. Commercial manufacturing commonly utilizes individual bioreactors ranging from approximately 2,000 L to 20,000 L, while large-scale commercial facilities typically combine multiple bioreactors into a production train. Effective annual capacity per production line depends on the number of bioreactors, culture cycle, product titer, batch success rate, and facility utilization. Single-use bioreactors offer shorter construction timelines, greater flexibility for product changeover, and lower cross-contamination risk, while large stainless-steel systems continue to provide significant economies of scale for mature, high-volume commercial products.
The upstream supply chain primarily consists of cell culture media, single-use bioprocess consumables, bioreactors, filtration systems, chromatography resins and columns, buffer materials, and sterile packaging components. Critical materials such as culture media, single-use consumables, and high-performance chromatography media can materially affect batch consistency and product quality. Major CMOs therefore typically establish multi-supplier strategies and safety stocks for critical materials while increasing facility utilization through standardized platform processes.
Regulatory compliance and quality systems constitute major competitive barriers. Biologics manufacturing must continuously comply with GMP requirements and maintain robust systems for quality management, data integrity, contamination control, process validation, and batch release. Once a commercial product has received regulatory approval and its manufacturing process has been validated at a specific CMO facility, transferring production to another site generally requires additional technology transfer, validation, and regulatory change procedures. The associated time and cost create relatively high customer stickiness and long contract durations for established commercial products.
Key competitive factors include commercial manufacturing experience, GMP compliance track record, manufacturing scale, capacity utilization, technology transfer efficiency, batch success rates, delivery reliability, and global manufacturing networks. Large CMOs with extensive bioreactor capacity and multiple manufacturing sites are well positioned to serve high-volume commercial antibody products, while mid-sized and specialized CMOs differentiate themselves through flexible capacity, small-batch manufacturing, complex molecule capabilities, or specialized technology platforms.
Profitability varies significantly depending on product type, manufacturing scale, capacity utilization, and development stage. Mature commercial biologics generally provide more stable batch demand and higher equipment utilization, whereas clinical-stage projects involve smaller batch volumes, frequent product changeovers, and greater project attrition. Gross margins for established biologics CMO manufacturing operations can generally fall within approximately 20%–40%. Large-scale antibody drug substance manufacturing can achieve stronger economies of scale at high utilization rates, while cell and gene therapy manufacturing and small-batch sterile fill-finish may command higher unit pricing but also require greater labor, quality control, and facility costs.
Future industry growth will be supported by the continued expansion of biologics pipelines, increasing commercialization of antibody drugs and emerging biologic modalities, efforts by pharmaceutical companies to reduce fixed-asset investment, and deeper specialization across pharmaceutical manufacturing networks. At the same time, major CMOs continue to add large-scale 20,000 L-class mammalian cell culture capacity, resulting in greater capacity availability in certain regions. Competition is therefore expected to gradually shift from pure capacity expansion toward a broader focus on capacity utilization, manufacturing efficiency, quality consistency, supply reliability, and lifecycle manufacturing capabilities.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Biologics CMO (Contract Manufacturing Organization) Services market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Lonza Group AG
Samsung Biologics Co., Ltd.
FUJIFILM Biotechnologies
Boehringer Ingelheim
WuXi Biologics (Cayman) Inc.
Thermo Fisher Scientific
Catalent, Inc.
AGC Biologics
National Resilience, Inc.
Vetter Pharma International GmbH
Rentschler Biopharma SE
KBI Biopharma, Inc.
LOTTE BIOLOGICS Co., Ltd.
Pfizer CentreOne
AbbVie Contract Manufacturing
Syngene International Limited
Avid Bioservices, Inc.
Recipharm Advanced Bio
Ajinomoto Bio-Pharma Services
Wacker Biotech GmbH
Bora Biologics
3PBIOVIAN
Fareva
Aenova Group
Siegfried Holding AG
GenScript ProBio
Chime Biologics (Wuhan) Co., Ltd.
MabPlex International
Pharmaron Beijing Co., Ltd.
Thousand Oaks Biologics Inc.
Cytovance Biologics, Inc.
Porton Pharma Solutions Ltd.
Segment by Type
Cell and Gene Therapies
Antibodies
Vaccines
Others
Segment by CMO Provider Type
In-house CMO
Independent CMO
Segment by Manufacturing Stage
Drug Substance (DS) Manufacturing
Drug Product (DP) Manufacturing
Segment by Application
Large Pharmaceutical and Biopharmaceutical Companies
Small and Mid-sized Pharmaceutical and Biotechnology Companies
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Biologics CMO (Contract Manufacturing Organization) Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Biologics CMO (Contract Manufacturing Organization) Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Biologics CMO (Contract Manufacturing Organization) Services Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Cell and Gene Therapies
1.2.3 Antibodies
1.2.4 Vaccines
1.2.5 Others
1.3 Market Segmentation by CMO Provider Type
1.3.1 Global Biologics CMO (Contract Manufacturing Organization) Services Market Size by CMO Provider Type, 2021 vs 2025 vs 2032
1.3.2 In-house CMO
1.3.3 Independent CMO
1.4 Market Segmentation by Manufacturing Stage
1.4.1 Global Biologics CMO (Contract Manufacturing Organization) Services Market Size by Manufacturing Stage, 2021 vs 2025 vs 2032
1.4.2 Drug Substance (DS) Manufacturing
1.4.3 Drug Product (DP) Manufacturing
1.5 Market Segmentation by Application
1.5.1 Global Biologics CMO (Contract Manufacturing Organization) Services Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Large Pharmaceutical and Biopharmaceutical Companies
1.5.3 Small and Mid-sized Pharmaceutical and Biotechnology Companies
1.5.4 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Biologics CMO (Contract Manufacturing Organization) Services Revenue Estimates and Forecasts (2021-2032)
2.2 Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Biologics CMO (Contract Manufacturing Organization) Services Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Biologics CMO (Contract Manufacturing Organization) Services Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Cell and Gene Therapies: Market Share by Key Players
3.3.2 Antibodies: Market Share by Key Players
3.3.3 Vaccines: Market Share by Key Players
3.3.4 Others: Market Share by Key Players
3.4 Global Biologics CMO (Contract Manufacturing Organization) Services Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Biologics CMO (Contract Manufacturing Organization) Services Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Biologics CMO (Contract Manufacturing Organization) Services Market by CMO Provider Type
4.2.1 Global Revenue by CMO Provider Type (2021-2032)
4.2.2 Global Revenue-Based Market Share by CMO Provider Type (2021-2032)
4.3 Global Biologics CMO (Contract Manufacturing Organization) Services Market by Manufacturing Stage
4.3.1 Global Revenue by Manufacturing Stage (2021-2032)
4.3.2 Global Revenue-Based Market Share by Manufacturing Stage (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Biologics CMO (Contract Manufacturing Organization) Services Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Biologics CMO (Contract Manufacturing Organization) Services Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Biologics CMO (Contract Manufacturing Organization) Services Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Biologics CMO (Contract Manufacturing Organization) Services Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Biologics CMO (Contract Manufacturing Organization) Services Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Biologics CMO (Contract Manufacturing Organization) Services Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Biologics CMO (Contract Manufacturing Organization) Services Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Biologics CMO (Contract Manufacturing Organization) Services Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Lonza Group AG
11.1.1 Lonza Group AG Corporation Information
11.1.2 Lonza Group AG Business Overview
11.1.3 Lonza Group AG Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.1.4 Lonza Group AG Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.1.5 Lonza Group AG Biologics CMO (Contract Manufacturing Organization) Services Revenue by Product in 2025
11.1.6 Lonza Group AG Biologics CMO (Contract Manufacturing Organization) Services Revenue by Application in 2025
11.1.7 Lonza Group AG Biologics CMO (Contract Manufacturing Organization) Services Revenue by Geographic Area in 2025
11.1.8 Lonza Group AG Biologics CMO (Contract Manufacturing Organization) Services SWOT Analysis
11.1.9 Lonza Group AG Recent Developments
11.2 Samsung Biologics Co., Ltd.
11.2.1 Samsung Biologics Co., Ltd. Corporation Information
11.2.2 Samsung Biologics Co., Ltd. Business Overview
11.2.3 Samsung Biologics Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.2.4 Samsung Biologics Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.2.5 Samsung Biologics Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue by Product in 2025
11.2.6 Samsung Biologics Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue by Application in 2025
11.2.7 Samsung Biologics Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue by Geographic Area in 2025
11.2.8 Samsung Biologics Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services SWOT Analysis
11.2.9 Samsung Biologics Co., Ltd. Recent Developments
11.3 FUJIFILM Biotechnologies
11.3.1 FUJIFILM Biotechnologies Corporation Information
11.3.2 FUJIFILM Biotechnologies Business Overview
11.3.3 FUJIFILM Biotechnologies Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.3.4 FUJIFILM Biotechnologies Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.3.5 FUJIFILM Biotechnologies Biologics CMO (Contract Manufacturing Organization) Services Revenue by Product in 2025
11.3.6 FUJIFILM Biotechnologies Biologics CMO (Contract Manufacturing Organization) Services Revenue by Application in 2025
11.3.7 FUJIFILM Biotechnologies Biologics CMO (Contract Manufacturing Organization) Services Revenue by Geographic Area in 2025
11.3.8 FUJIFILM Biotechnologies Biologics CMO (Contract Manufacturing Organization) Services SWOT Analysis
11.3.9 FUJIFILM Biotechnologies Recent Developments
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Corporation Information
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.4.4 Boehringer Ingelheim Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.4.5 Boehringer Ingelheim Biologics CMO (Contract Manufacturing Organization) Services Revenue by Product in 2025
11.4.6 Boehringer Ingelheim Biologics CMO (Contract Manufacturing Organization) Services Revenue by Application in 2025
11.4.7 Boehringer Ingelheim Biologics CMO (Contract Manufacturing Organization) Services Revenue by Geographic Area in 2025
11.4.8 Boehringer Ingelheim Biologics CMO (Contract Manufacturing Organization) Services SWOT Analysis
11.4.9 Boehringer Ingelheim Recent Developments
11.5 WuXi Biologics (Cayman) Inc.
11.5.1 WuXi Biologics (Cayman) Inc. Corporation Information
11.5.2 WuXi Biologics (Cayman) Inc. Business Overview
11.5.3 WuXi Biologics (Cayman) Inc. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.5.4 WuXi Biologics (Cayman) Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.5.5 WuXi Biologics (Cayman) Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue by Product in 2025
11.5.6 WuXi Biologics (Cayman) Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue by Application in 2025
11.5.7 WuXi Biologics (Cayman) Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue by Geographic Area in 2025
11.5.8 WuXi Biologics (Cayman) Inc. Biologics CMO (Contract Manufacturing Organization) Services SWOT Analysis
11.5.9 WuXi Biologics (Cayman) Inc. Recent Developments
11.6 Thermo Fisher Scientific
11.6.1 Thermo Fisher Scientific Corporation Information
11.6.2 Thermo Fisher Scientific Business Overview
11.6.3 Thermo Fisher Scientific Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.6.4 Thermo Fisher Scientific Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.6.5 Thermo Fisher Scientific Recent Developments
11.7 Catalent, Inc.
11.7.1 Catalent, Inc. Corporation Information
11.7.2 Catalent, Inc. Business Overview
11.7.3 Catalent, Inc. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.7.4 Catalent, Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.7.5 Catalent, Inc. Recent Developments
11.8 AGC Biologics
11.8.1 AGC Biologics Corporation Information
11.8.2 AGC Biologics Business Overview
11.8.3 AGC Biologics Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.8.4 AGC Biologics Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.8.5 AGC Biologics Recent Developments
11.9 National Resilience, Inc.
11.9.1 National Resilience, Inc. Corporation Information
11.9.2 National Resilience, Inc. Business Overview
11.9.3 National Resilience, Inc. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.9.4 National Resilience, Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.9.5 National Resilience, Inc. Recent Developments
11.10 Vetter Pharma International GmbH
11.10.1 Vetter Pharma International GmbH Corporation Information
11.10.2 Vetter Pharma International GmbH Business Overview
11.10.3 Vetter Pharma International GmbH Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.10.4 Vetter Pharma International GmbH Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Rentschler Biopharma SE
11.11.1 Rentschler Biopharma SE Corporation Information
11.11.2 Rentschler Biopharma SE Business Overview
11.11.3 Rentschler Biopharma SE Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.11.4 Rentschler Biopharma SE Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.11.5 Rentschler Biopharma SE Recent Developments
11.12 KBI Biopharma, Inc.
11.12.1 KBI Biopharma, Inc. Corporation Information
11.12.2 KBI Biopharma, Inc. Business Overview
11.12.3 KBI Biopharma, Inc. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.12.4 KBI Biopharma, Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.12.5 KBI Biopharma, Inc. Recent Developments
11.13 LOTTE BIOLOGICS Co., Ltd.
11.13.1 LOTTE BIOLOGICS Co., Ltd. Corporation Information
11.13.2 LOTTE BIOLOGICS Co., Ltd. Business Overview
11.13.3 LOTTE BIOLOGICS Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.13.4 LOTTE BIOLOGICS Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.13.5 LOTTE BIOLOGICS Co., Ltd. Recent Developments
11.14 Pfizer CentreOne
11.14.1 Pfizer CentreOne Corporation Information
11.14.2 Pfizer CentreOne Business Overview
11.14.3 Pfizer CentreOne Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.14.4 Pfizer CentreOne Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.14.5 Pfizer CentreOne Recent Developments
11.15 AbbVie Contract Manufacturing
11.15.1 AbbVie Contract Manufacturing Corporation Information
11.15.2 AbbVie Contract Manufacturing Business Overview
11.15.3 AbbVie Contract Manufacturing Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.15.4 AbbVie Contract Manufacturing Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.15.5 AbbVie Contract Manufacturing Recent Developments
11.16 Syngene International Limited
11.16.1 Syngene International Limited Corporation Information
11.16.2 Syngene International Limited Business Overview
11.16.3 Syngene International Limited Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.16.4 Syngene International Limited Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.16.5 Syngene International Limited Recent Developments
11.17 Avid Bioservices, Inc.
11.17.1 Avid Bioservices, Inc. Corporation Information
11.17.2 Avid Bioservices, Inc. Business Overview
11.17.3 Avid Bioservices, Inc. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.17.4 Avid Bioservices, Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.17.5 Avid Bioservices, Inc. Recent Developments
11.18 Recipharm Advanced Bio
11.18.1 Recipharm Advanced Bio Corporation Information
11.18.2 Recipharm Advanced Bio Business Overview
11.18.3 Recipharm Advanced Bio Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.18.4 Recipharm Advanced Bio Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.18.5 Recipharm Advanced Bio Recent Developments
11.19 Ajinomoto Bio-Pharma Services
11.19.1 Ajinomoto Bio-Pharma Services Corporation Information
11.19.2 Ajinomoto Bio-Pharma Services Business Overview
11.19.3 Ajinomoto Bio-Pharma Services Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.19.4 Ajinomoto Bio-Pharma Services Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.19.5 Ajinomoto Bio-Pharma Services Recent Developments
11.20 Wacker Biotech GmbH
11.20.1 Wacker Biotech GmbH Corporation Information
11.20.2 Wacker Biotech GmbH Business Overview
11.20.3 Wacker Biotech GmbH Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.20.4 Wacker Biotech GmbH Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.20.5 Wacker Biotech GmbH Recent Developments
11.21 Bora Biologics
11.21.1 Bora Biologics Corporation Information
11.21.2 Bora Biologics Business Overview
11.21.3 Bora Biologics Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.21.4 Bora Biologics Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.21.5 Bora Biologics Recent Developments
11.22 3PBIOVIAN
11.22.1 3PBIOVIAN Corporation Information
11.22.2 3PBIOVIAN Business Overview
11.22.3 3PBIOVIAN Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.22.4 3PBIOVIAN Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.22.5 3PBIOVIAN Recent Developments
11.23 Fareva
11.23.1 Fareva Corporation Information
11.23.2 Fareva Business Overview
11.23.3 Fareva Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.23.4 Fareva Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.23.5 Fareva Recent Developments
11.24 Aenova Group
11.24.1 Aenova Group Corporation Information
11.24.2 Aenova Group Business Overview
11.24.3 Aenova Group Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.24.4 Aenova Group Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.24.5 Aenova Group Recent Developments
11.25 Siegfried Holding AG
11.25.1 Siegfried Holding AG Corporation Information
11.25.2 Siegfried Holding AG Business Overview
11.25.3 Siegfried Holding AG Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.25.4 Siegfried Holding AG Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.25.5 Siegfried Holding AG Recent Developments
11.26 GenScript ProBio
11.26.1 GenScript ProBio Corporation Information
11.26.2 GenScript ProBio Business Overview
11.26.3 GenScript ProBio Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.26.4 GenScript ProBio Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.26.5 GenScript ProBio Recent Developments
11.27 Chime Biologics (Wuhan) Co., Ltd.
11.27.1 Chime Biologics (Wuhan) Co., Ltd. Corporation Information
11.27.2 Chime Biologics (Wuhan) Co., Ltd. Business Overview
11.27.3 Chime Biologics (Wuhan) Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.27.4 Chime Biologics (Wuhan) Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.27.5 Chime Biologics (Wuhan) Co., Ltd. Recent Developments
11.28 MabPlex International
11.28.1 MabPlex International Corporation Information
11.28.2 MabPlex International Business Overview
11.28.3 MabPlex International Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.28.4 MabPlex International Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.28.5 MabPlex International Recent Developments
11.29 Pharmaron Beijing Co., Ltd.
11.29.1 Pharmaron Beijing Co., Ltd. Corporation Information
11.29.2 Pharmaron Beijing Co., Ltd. Business Overview
11.29.3 Pharmaron Beijing Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.29.4 Pharmaron Beijing Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.29.5 Pharmaron Beijing Co., Ltd. Recent Developments
11.30 Thousand Oaks Biologics Inc.
11.30.1 Thousand Oaks Biologics Inc. Corporation Information
11.30.2 Thousand Oaks Biologics Inc. Business Overview
11.30.3 Thousand Oaks Biologics Inc. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.30.4 Thousand Oaks Biologics Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.30.5 Thousand Oaks Biologics Inc. Recent Developments
11.31 Cytovance Biologics, Inc.
11.31.1 Cytovance Biologics, Inc. Corporation Information
11.31.2 Cytovance Biologics, Inc. Business Overview
11.31.3 Cytovance Biologics, Inc. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.31.4 Cytovance Biologics, Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.31.5 Cytovance Biologics, Inc. Recent Developments
11.32 Porton Pharma Solutions Ltd.
11.32.1 Porton Pharma Solutions Ltd. Corporation Information
11.32.2 Porton Pharma Solutions Ltd. Business Overview
11.32.3 Porton Pharma Solutions Ltd. Biologics CMO (Contract Manufacturing Organization) Services Product Features and Attributes
11.32.4 Porton Pharma Solutions Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue and Gross Margin (2021-2026)
11.32.5 Porton Pharma Solutions Ltd. Recent Developments

12 Biologics CMO (Contract Manufacturing Organization) Services Value Chain and Ecosystem Analysis
12.1 Biologics CMO (Contract Manufacturing Organization) Services Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Biologics CMO (Contract Manufacturing Organization) Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Biologics CMO (Contract Manufacturing Organization) Services Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Biologics CMO (Contract Manufacturing Organization) Services Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Biologics CMO (Contract Manufacturing Organization) Services Market Size Growth Rate by CMO Provider Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Biologics CMO (Contract Manufacturing Organization) Services Market Size Growth Rate by Manufacturing Stage, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Biologics CMO (Contract Manufacturing Organization) Services Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Region (US$ Million), 2021-2026
Table 7. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Players (US$ Million), 2021-2026
Table 10. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biologics CMO (Contract Manufacturing Organization) Services Revenue, 2025
Table 13. Global Biologics CMO (Contract Manufacturing Organization) Services Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Biologics CMO (Contract Manufacturing Organization) Services Companies Headquarters
Table 15. Global Biologics CMO (Contract Manufacturing Organization) Services Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Type (US$ Million), 2021-2026
Table 19. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Type (US$ Million), 2027-2032
Table 20. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by CMO Provider Type (US$ Million), 2021-2026
Table 21. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by CMO Provider Type (US$ Million), 2027-2032
Table 22. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Manufacturing Stage (US$ Million), 2021-2026
Table 23. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Manufacturing Stage (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Application (US$ Million), 2021-2026
Table 26. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue by Application (US$ Million), 2027-2032
Table 27. Biologics CMO (Contract Manufacturing Organization) Services High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Biologics CMO (Contract Manufacturing Organization) Services Growth Accelerators and Market Barriers
Table 31. North America Biologics CMO (Contract Manufacturing Organization) Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Biologics CMO (Contract Manufacturing Organization) Services Growth Accelerators and Market Barriers
Table 33. Europe Biologics CMO (Contract Manufacturing Organization) Services Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Biologics CMO (Contract Manufacturing Organization) Services Investment Opportunities and Key Challenges
Table 37. Central and South America Biologics CMO (Contract Manufacturing Organization) Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Biologics CMO (Contract Manufacturing Organization) Services Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Biologics CMO (Contract Manufacturing Organization) Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Lonza Group AG Corporation Information
Table 41. Lonza Group AG Description and Major Businesses
Table 42. Lonza Group AG Product Features and Attributes
Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Lonza Group AG Revenue Proportion by Product in 2025
Table 45. Lonza Group AG Revenue Proportion by Application in 2025
Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025
Table 47. Lonza Group AG Biologics CMO (Contract Manufacturing Organization) Services SWOT Analysis
Table 48. Lonza Group AG Recent Developments
Table 49. Samsung Biologics Co., Ltd. Corporation Information
Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses
Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes
Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025
Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025
Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025
Table 56. Samsung Biologics Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services SWOT Analysis
Table 57. Samsung Biologics Co., Ltd. Recent Developments
Table 58. FUJIFILM Biotechnologies Corporation Information
Table 59. FUJIFILM Biotechnologies Description and Major Businesses
Table 60. FUJIFILM Biotechnologies Product Features and Attributes
Table 61. FUJIFILM Biotechnologies Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. FUJIFILM Biotechnologies Revenue Proportion by Product in 2025
Table 63. FUJIFILM Biotechnologies Revenue Proportion by Application in 2025
Table 64. FUJIFILM Biotechnologies Revenue Proportion by Geographic Area in 2025
Table 65. FUJIFILM Biotechnologies Biologics CMO (Contract Manufacturing Organization) Services SWOT Analysis
Table 66. FUJIFILM Biotechnologies Recent Developments
Table 67. Boehringer Ingelheim Corporation Information
Table 68. Boehringer Ingelheim Description and Major Businesses
Table 69. Boehringer Ingelheim Product Features and Attributes
Table 70. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 72. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 73. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 74. Boehringer Ingelheim Biologics CMO (Contract Manufacturing Organization) Services SWOT Analysis
Table 75. Boehringer Ingelheim Recent Developments
Table 76. WuXi Biologics (Cayman) Inc. Corporation Information
Table 77. WuXi Biologics (Cayman) Inc. Description and Major Businesses
Table 78. WuXi Biologics (Cayman) Inc. Product Features and Attributes
Table 79. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025
Table 81. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025
Table 82. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025
Table 83. WuXi Biologics (Cayman) Inc. Biologics CMO (Contract Manufacturing Organization) Services SWOT Analysis
Table 84. WuXi Biologics (Cayman) Inc. Recent Developments
Table 85. Thermo Fisher Scientific Corporation Information
Table 86. Thermo Fisher Scientific Description and Major Businesses
Table 87. Thermo Fisher Scientific Product Features and Attributes
Table 88. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Thermo Fisher Scientific Recent Developments
Table 90. Catalent, Inc. Corporation Information
Table 91. Catalent, Inc. Description and Major Businesses
Table 92. Catalent, Inc. Product Features and Attributes
Table 93. Catalent, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Catalent, Inc. Recent Developments
Table 95. AGC Biologics Corporation Information
Table 96. AGC Biologics Description and Major Businesses
Table 97. AGC Biologics Product Features and Attributes
Table 98. AGC Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. AGC Biologics Recent Developments
Table 100. National Resilience, Inc. Corporation Information
Table 101. National Resilience, Inc. Description and Major Businesses
Table 102. National Resilience, Inc. Product Features and Attributes
Table 103. National Resilience, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. National Resilience, Inc. Recent Developments
Table 105. Vetter Pharma International GmbH Corporation Information
Table 106. Vetter Pharma International GmbH Description and Major Businesses
Table 107. Vetter Pharma International GmbH Product Features and Attributes
Table 108. Vetter Pharma International GmbH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Vetter Pharma International GmbH Recent Developments
Table 110. Rentschler Biopharma SE Corporation Information
Table 111. Rentschler Biopharma SE Description and Major Businesses
Table 112. Rentschler Biopharma SE Product Features and Attributes
Table 113. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Rentschler Biopharma SE Recent Developments
Table 115. KBI Biopharma, Inc. Corporation Information
Table 116. KBI Biopharma, Inc. Description and Major Businesses
Table 117. KBI Biopharma, Inc. Product Features and Attributes
Table 118. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. KBI Biopharma, Inc. Recent Developments
Table 120. LOTTE BIOLOGICS Co., Ltd. Corporation Information
Table 121. LOTTE BIOLOGICS Co., Ltd. Description and Major Businesses
Table 122. LOTTE BIOLOGICS Co., Ltd. Product Features and Attributes
Table 123. LOTTE BIOLOGICS Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. LOTTE BIOLOGICS Co., Ltd. Recent Developments
Table 125. Pfizer CentreOne Corporation Information
Table 126. Pfizer CentreOne Description and Major Businesses
Table 127. Pfizer CentreOne Product Features and Attributes
Table 128. Pfizer CentreOne Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Pfizer CentreOne Recent Developments
Table 130. AbbVie Contract Manufacturing Corporation Information
Table 131. AbbVie Contract Manufacturing Description and Major Businesses
Table 132. AbbVie Contract Manufacturing Product Features and Attributes
Table 133. AbbVie Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. AbbVie Contract Manufacturing Recent Developments
Table 135. Syngene International Limited Corporation Information
Table 136. Syngene International Limited Description and Major Businesses
Table 137. Syngene International Limited Product Features and Attributes
Table 138. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Syngene International Limited Recent Developments
Table 140. Avid Bioservices, Inc. Corporation Information
Table 141. Avid Bioservices, Inc. Description and Major Businesses
Table 142. Avid Bioservices, Inc. Product Features and Attributes
Table 143. Avid Bioservices, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Avid Bioservices, Inc. Recent Developments
Table 145. Recipharm Advanced Bio Corporation Information
Table 146. Recipharm Advanced Bio Description and Major Businesses
Table 147. Recipharm Advanced Bio Product Features and Attributes
Table 148. Recipharm Advanced Bio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Recipharm Advanced Bio Recent Developments
Table 150. Ajinomoto Bio-Pharma Services Corporation Information
Table 151. Ajinomoto Bio-Pharma Services Description and Major Businesses
Table 152. Ajinomoto Bio-Pharma Services Product Features and Attributes
Table 153. Ajinomoto Bio-Pharma Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Ajinomoto Bio-Pharma Services Recent Developments
Table 155. Wacker Biotech GmbH Corporation Information
Table 156. Wacker Biotech GmbH Description and Major Businesses
Table 157. Wacker Biotech GmbH Product Features and Attributes
Table 158. Wacker Biotech GmbH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Wacker Biotech GmbH Recent Developments
Table 160. Bora Biologics Corporation Information
Table 161. Bora Biologics Description and Major Businesses
Table 162. Bora Biologics Product Features and Attributes
Table 163. Bora Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Bora Biologics Recent Developments
Table 165. 3PBIOVIAN Corporation Information
Table 166. 3PBIOVIAN Description and Major Businesses
Table 167. 3PBIOVIAN Product Features and Attributes
Table 168. 3PBIOVIAN Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. 3PBIOVIAN Recent Developments
Table 170. Fareva Corporation Information
Table 171. Fareva Description and Major Businesses
Table 172. Fareva Product Features and Attributes
Table 173. Fareva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Fareva Recent Developments
Table 175. Aenova Group Corporation Information
Table 176. Aenova Group Description and Major Businesses
Table 177. Aenova Group Product Features and Attributes
Table 178. Aenova Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Aenova Group Recent Developments
Table 180. Siegfried Holding AG Corporation Information
Table 181. Siegfried Holding AG Description and Major Businesses
Table 182. Siegfried Holding AG Product Features and Attributes
Table 183. Siegfried Holding AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Siegfried Holding AG Recent Developments
Table 185. GenScript ProBio Corporation Information
Table 186. GenScript ProBio Description and Major Businesses
Table 187. GenScript ProBio Product Features and Attributes
Table 188. GenScript ProBio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. GenScript ProBio Recent Developments
Table 190. Chime Biologics (Wuhan) Co., Ltd. Corporation Information
Table 191. Chime Biologics (Wuhan) Co., Ltd. Description and Major Businesses
Table 192. Chime Biologics (Wuhan) Co., Ltd. Product Features and Attributes
Table 193. Chime Biologics (Wuhan) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Chime Biologics (Wuhan) Co., Ltd. Recent Developments
Table 195. MabPlex International Corporation Information
Table 196. MabPlex International Description and Major Businesses
Table 197. MabPlex International Product Features and Attributes
Table 198. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. MabPlex International Recent Developments
Table 200. Pharmaron Beijing Co., Ltd. Corporation Information
Table 201. Pharmaron Beijing Co., Ltd. Description and Major Businesses
Table 202. Pharmaron Beijing Co., Ltd. Product Features and Attributes
Table 203. Pharmaron Beijing Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Pharmaron Beijing Co., Ltd. Recent Developments
Table 205. Thousand Oaks Biologics Inc. Corporation Information
Table 206. Thousand Oaks Biologics Inc. Description and Major Businesses
Table 207. Thousand Oaks Biologics Inc. Product Features and Attributes
Table 208. Thousand Oaks Biologics Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Thousand Oaks Biologics Inc. Recent Developments
Table 210. Cytovance Biologics, Inc. Corporation Information
Table 211. Cytovance Biologics, Inc. Description and Major Businesses
Table 212. Cytovance Biologics, Inc. Product Features and Attributes
Table 213. Cytovance Biologics, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Cytovance Biologics, Inc. Recent Developments
Table 215. Porton Pharma Solutions Ltd. Corporation Information
Table 216. Porton Pharma Solutions Ltd. Description and Major Businesses
Table 217. Porton Pharma Solutions Ltd. Product Features and Attributes
Table 218. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Porton Pharma Solutions Ltd. Recent Developments
Table 220. Technologies, Platforms and Infrastructure
Table 221. Distributors List
Table 222. Market Trends and Market Evolution
Table 223. Market Drivers and Opportunities
Table 224. Market Challenges, Risks, and Restraints
Table 225. Research Programs/Design for This Report
Table 226. Key Data Information from Secondary Sources
Table 227. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Biologics CMO (Contract Manufacturing Organization) Services Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Cell and Gene Therapies Product Picture
Figure 3. Antibodies Product Picture
Figure 4. Vaccines Product Picture
Figure 5. Others Product Picture
Figure 6. Global Biologics CMO (Contract Manufacturing Organization) Services Market Size Growth Rate by CMO Provider Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. In-house CMO Product Picture
Figure 8. Independent CMO Product Picture
Figure 9. Global Biologics CMO (Contract Manufacturing Organization) Services Market Size Growth Rate by Manufacturing Stage, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Drug Substance (DS) Manufacturing Product Picture
Figure 11. Drug Product (DP) Manufacturing Product Picture
Figure 12. Global Biologics CMO (Contract Manufacturing Organization) Services Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 13. Large Pharmaceutical and Biopharmaceutical Companies
Figure 14. Small and Mid-sized Pharmaceutical and Biotechnology Companies
Figure 15. Others
Figure 16. Biologics CMO (Contract Manufacturing Organization) Services Report Years Considered
Figure 17. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 19. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 20. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue-Based Market Share by Region (2021-2032)
Figure 21. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue-Based Market Share Ranking (2025)
Figure 22. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 23. Cell and Gene Therapies Revenue-Based Market Share by Player in 2025
Figure 24. Antibodies Revenue-Based Market Share by Player in 2025
Figure 25. Vaccines Revenue-Based Market Share by Player in 2025
Figure 26. Others Revenue-Based Market Share by Player in 2025
Figure 27. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue-Based Market Share by Type (2021-2032)
Figure 28. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue-Based Market Share by CMO Provider Type (2021-2032)
Figure 29. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue-Based Market Share by Manufacturing Stage (2021-2032)
Figure 30. Global Biologics CMO (Contract Manufacturing Organization) Services Revenue-Based Market Share by Application (2021-2032)
Figure 31. North America Biologics CMO (Contract Manufacturing Organization) Services Revenue YoY (US$ Million), 2021-2032
Figure 32. North America Top 5 Players Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million) in 2025
Figure 33. North America Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million) by Application (2021-2032)
Figure 34. US Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 35. Canada Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 36. Mexico Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 37. Europe Biologics CMO (Contract Manufacturing Organization) Services Revenue YoY (US$ Million), 2021-2032
Figure 38. Europe Top 5 Players Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million) in 2025
Figure 39. Europe Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million) by Application (2021-2032)
Figure 40. Germany Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 41. France Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 42. U.K. Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 43. Italy Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 44. Russia Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 45. Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Revenue YoY (US$ Million), 2021-2032
Figure 46. Asia-Pacific Top 8 Players Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million) in 2025
Figure 47. Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million) by Application (2021-2032)
Figure 48. Indonesia Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 49. Japan Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 50. South Korea Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 51. Australia Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 52. India Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 53. Indonesia Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 54. Vietnam Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 55. Malaysia Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 56. Philippines Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 57. Singapore Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 58. Central and South America Biologics CMO (Contract Manufacturing Organization) Services Revenue YoY (US$ Million), 2021-2032
Figure 59. Central and South America Top 5 Players Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million) in 2025
Figure 60. Central and South America Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million) by Application (2021-2032)
Figure 61. Brazil Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 62. Argentina Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 63. Middle East and Africa Biologics CMO (Contract Manufacturing Organization) Services Revenue YoY (US$ Million), 2021-2032
Figure 64. Middle East and Africa Top 5 Players Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million) in 2025
Figure 65. Middle East and Africa Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million) by Application (2021-2032)
Figure 66. GCC Countries Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 67. Israel Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 68. Egypt Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 69. South Africa Biologics CMO (Contract Manufacturing Organization) Services Revenue (US$ Million), 2021-2032
Figure 70. Biologics CMO (Contract Manufacturing Organization) Services Value Chain Mapping
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed